2019 European Society for Medical Oncology Congress Coverage

Save as Favorite
Sign in to receive recommendations (Learn more)

Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We’re proud to present our coverage below.

Research News:

Adding Keytruda to Chemotherapy Before Surgery for Early-Stage, Triple-Negative Breast Cancer Improves Response to Treatment

Kisqali Plus Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Verzenio Plus Faslodex Improves Overall Survival by 9 Months in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Podcast Episodes:

Immunotherapy Keytruda for Early-Stage Triple-Negative Breast Cancer: Better pCR and Lower Recurrence Rates: ESMO 2019 Coverage
Peter Schmid, M.D., Ph.D.

Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage
Leisha Emens, M.D.

Verzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status
George W. Sledge, Jr., M.D.

"CDK4/6 Inhibitor Plus Hormonal Therapy Should Be First Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO 2019 Coverage
Dennis Slamon, M.D.

Where Are We With Immunotherapy for Breast Cancer? ESMO 2019 Coverage
Jennifer Litton, M.D.

Heard in the Halls Mini Episodes:

Breast Cancer Research Highlights -- Heard in the Halls: Voices From ESMO 2019
Anne White, BS

People Satisfied With Decision to Use Scalp Cooling, Even If It's Not Effective -- Heard in the Halls: Voices From ESMO 2019
Conleth Murphy, M.D.


Was this article helpful? Yes / No

Fy20eoy sidebar v02.1
Back to Top